{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:08:25Z","timestamp":1792786105843,"version":"4.5.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Nippon Medical School Graduate School of Medicine, along with a research grant for Grants-in-Aid for Scientific Research","award":["23K07884"],"award-info":[{"award-number":["23K07884"]}],"id":[{"id":"https:\/\/ror.org\/00krab219","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate whether the modified disease activity index (mDAI) predicts subsequent disease progression and organ damage in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 227 patients diagnosed with SSc who were enrolled in a prospective SSc registry. Baseline disease activity was assessed using the modified EUSTAR disease activity index (mDAI), with active disease being defined as an mDAI of \u22652.5. The primary outcome was a composite of disease-related clinically meaningful complications\u2014based on revised CRISS step 1 events (interstitial lung disease progression, precapillary pulmonary hypertension, scleroderma renal crisis, heart failure, severe digital ischaemia, or severe gastrointestinal dysfunction)\u2014or all-cause mortality. Associations were examined using Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, 42 (18.5%) had active disease. During a median follow-up period of 38\u2009months, 45 (19.7%) patients had experienced the primary outcome. Active disease was associated with a higher risk of events (log-rank P\u2009&amp;lt;\u20090.001). In multivariable analysis, baseline active disease [hazard ratio (HR) 2.21, 95% CI 1.06\u20134.59] and a lower forced vital capacity (HR 0.98 per %, 95% CI 0.96\u20130.99) independently predicted adverse outcomes. Results were consistent across sensitivity analyses using alternative end point definitions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline mDAI and forced vital capacity independently predict disease-related clinically meaningful complications and mortality in SSc. The mDAI provides a simple, feasible tool for risk stratification beyond progression of interstitial lung disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag481","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T08:12:55Z","timestamp":1788509575000},"source":"Crossref","is-referenced-by-count":0,"title":["Baseline disease activity index and forced vital capacity predict clinically meaningful complications and mortality in systemic sclerosis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9520-2665","authenticated-orcid":false,"given":"Tsai-Hung","family":"Yen","sequence":"first","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung,","place":["Taiwan"]},{"name":"Division of General Medicine, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-573X","authenticated-orcid":false,"given":"Yohei","family":"Isomura","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Nan","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital , Taichung,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-6136","authenticated-orcid":false,"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine , Tokyo,","place":["Japan"]},{"name":"Scleroderma\/Myositis Centre of Excellence, Nippon Medical School Hospital , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"2026092513490167800_keag481-B1","doi-asserted-by":"crossref","first-page":"e001694","DOI":"10.1136\/rmdopen-2021-001694","article-title":"All-cause mortality in systemic rheumatic diseases under treatment compared with the general population, 2015-2019","volume":"7","author":"Bournia","year":"2021","journal-title":"RMD Open"},{"key":"2026092513490167800_keag481-B2","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","article-title":"Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis","volume":"43","author":"Kuwana","year":"2000","journal-title":"Arthritis Rheum"},{"key":"2026092513490167800_keag481-B3","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2026092513490167800_keag481-B4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/art.24433","article-title":"Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment","volume":"60","author":"Aletaha","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026092513490167800_keag481-B5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40674-025-00224-y","article-title":"Defining disease activity in systemic sclerosis","volume":"11","author":"Ross","year":"2025","journal-title":"Curr Treat Options in Rheum"},{"key":"2026092513490167800_keag481-B6","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1002\/art.42939","article-title":"Development and initial validation of the novel scleroderma clinical trials consortium activity index","volume":"76","author":"Ross","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026092513490167800_keag481-B7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/annrheumdis-2023-eular.2262","article-title":"POS1246 effects of nintedanib in patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSC-ILD) in subgroups by disease activity index","volume":"82","author":"Herrick","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/23971983241291923","article-title":"A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: study design and rationale of the VITALISScE\u2122 study","volume":"10","author":"Khanna","year":"2025","journal-title":"J Scleroderma Relat Disord"},{"key":"2026092513490167800_keag481-B10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology composite response index in systemic sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American College of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026092513490167800_keag481-B12","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/annrheumdis-2019-215787","article-title":"Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual","volume":"78","author":"Fasano","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B13","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/art.1780340405","article-title":"Predictors of survival in systemic sclerosis (scleroderma)","volume":"34","author":"Altman","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2026092513490167800_keag481-B15","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/annrheumdis-2014-205897","article-title":"Digital ulcers predict a worse disease course in patients with systemic sclerosis","volume":"75","author":"Mihai","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026092513490167800_keag481-B16","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2026092513490167800_keag481-B17","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/ar3876","article-title":"N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study","volume":"14","author":"Thakkar","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"2026092513490167800_keag481-B18","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/acr.21716","article-title":"Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group","volume":"64","author":"Muangchan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026092513490167800_keag481-B19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/23971983211040608","article-title":"NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: findings from the Canadian Scleroderma Research Group","volume":"7","author":"Jha","year":"2022","journal-title":"J Scleroderma Relat Disord"},{"key":"2026092513490167800_keag481-B20","author":"Hoffmann-Vold","journal-title":"J Scleroderma Relat Disord. in press."}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag481\/70951933\/keag481.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/9\/keag481\/70951933\/keag481.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/9\/keag481\/70951933\/keag481.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:49:09Z","timestamp":1790358549000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag481\/8785297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag481","relation":{},"ISSN":["1462-0332"],"issn-type":[{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,9,1]]},"article-number":"keag481"}}